IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v22y2002i4p340-349.html

Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)

Author

Listed:
  • Philip Clarke

    (Health Economic Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Oxford, United Kingdom)

  • Alastair Gray

    (Health Economic Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Oxford, United Kingdom)

  • Rury Holman

    (Diabetes Trials Unit, Radcliffe Infirmary, Oxford, United Kingdom)

Abstract

Purpose . The aim of this study was to analyze quality-of-life data from the United Kingdom Prospective Diabetes Study (UKPDS) to estimate the impact of diabetes-related complications on utility-based measures of quality of life. Methods . The EuroQol EQ-5D instrument was administered in 1996 to 3667 UKPDS patients with type 2 diabetes. Tobit and censored least absolute deviations (CLAD) regression analysis based on data from the 3192 respondents was used to estimate the impact of major complications on (1) the visual analog scale (VAS) and (2) the EQ-5D utilities derived from population-based time trade-off values. Results . Using the tobit model, the effect on tariff values was as follows: myocardial infarction = -0.055 (95% confidence interval [CI] = -0.067, -0.042), blindness in 1 eye = -0.074 (95% CI = -0.124, -0.052), ischemic heart disease = -0.090 (95% CI = -0.126, -0.054), heart failure = -0.108 (95% CI = -0.169, -0.048), stroke = -0.164 (95% CI = -0.222, -0.105), and amputation = -0.280 (95% CI = -0.389, -0.170). The impact on the VAS scores was smaller, but the ranking was identical. Estimates of these effects, based on the nonparametric CLAD estimator, are also reported and compared. Conclusion . These results demonstrate the magnitude of the impact of 6 complications on utility-based measures of quality of life, which can be used to estimate the outcome of interventions that reduce these diabetes-related complications.

Suggested Citation

  • Philip Clarke & Alastair Gray & Rury Holman, 2002. "Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)," Medical Decision Making, , vol. 22(4), pages 340-349, August.
    • Handle: RePEc:sae:medema:v:22:y:2002:i:4:p:340-349
    DOI: 10.1177/0272989X0202200412
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0272989X0202200412
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0272989X0202200412?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Greene, William, 1999. "Marginal effects in the censored regression model," Economics Letters, Elsevier, vol. 64(1), pages 43-49, July.
    2. Mullahy, John, 1998. "Much ado about two: reconsidering retransformation and the two-part model in health econometrics," Journal of Health Economics, Elsevier, vol. 17(3), pages 247-281, June.
    3. A. J. Culyer & J. P. Newhouse (ed.), 2000. "Handbook of Health Economics," Handbook of Health Economics, Elsevier, edition 1, volume 1, number 1.
    4. Ruud, Paul A., 2000. "An Introduction to Classical Econometric Theory," OUP Catalogue, Oxford University Press, number 9780195111644.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Neale Cohen & Michael Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William Valentine & Andrew Palmer, 2007. "Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin," PharmacoEconomics, Springer, vol. 25(10), pages 881-897, October.
    2. Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
    3. Billingsley Kaambwa & Lucinda Billingham & Stirling Bryan, 2013. "Mapping utility scores from the Barthel index," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 231-241, April.
    4. Irina Odnoletkova & Dirk Ramaekers & Frank Nobels & Geert Goderis & Bert Aertgeerts & Lieven Annemans, 2016. "Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
    5. John Yfantopoulos & Athanasios Chantzaras, 2020. "Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 729-743, July.
    6. Sandra Tunis & Luc Sauriol & Michael Minshall, 2010. "Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada," Applied Health Economics and Health Policy, Springer, vol. 8(4), pages 267-280, July.
    7. Mason, J.E. & Denton, B.T. & Shah, N.D. & Smith, S.A., 2014. "Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 727-738.
    8. Aliasghar A. Kiadaliri & Ulf-G Gerdtham & Björn Eliasson & Soffia Gudbjörnsdottir & Ann-Marie Svensson & Katarina Steen Carlsson, 2014. "Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden," IJERPH, MDPI, vol. 11(5), pages 1-14, May.
    9. Jeremy Chancellor & Samuel Aballéa & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant, 2008. "Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens," PharmacoEconomics, Springer, vol. 26(3), pages 217-234, March.
    10. Shuyan Gu & Yuhang Zeng & Demin Yu & Xiaoqian Hu & Hengjin Dong, 2016. "Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-21, November.
    11. Pirhonen, Laura & Olofsson, Elisabeth Hansson & Fors, Andreas & Ekman, Inger & Bolin, Kristian, 2017. "Effects of person-centred care on health outcomes—A randomized controlled trial in patients with acute coronary syndrome," Health Policy, Elsevier, vol. 121(2), pages 169-179.
    12. Antonio García-Ruiz & Lucía Pérez-Costillas & Ana Montesinos & Javier Alcalde & Itziar Oyagüez & Miguel Casado, 2012. "Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    13. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    14. Mengjun Wu & John Brazier & Benjamin Kearns & Clare Relton & Christine Smith & Cindy Cooper, 2015. "Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 141-151, March.
    15. Brian T. Denton & Murat Kurt & Nilay D. Shah & Sandra C. Bryant & Steven A. Smith, 2009. "Optimizing the Start Time of Statin Therapy for Patients with Diabetes," Medical Decision Making, , vol. 29(3), pages 351-367, May.
    16. José M. Labeaga & Xisco Oliver & Amedeo Spadaro, "undated". "Measuring Changes in Health Capital," Working Papers 2005-15, FEDEA.
    17. Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos, 2007. "A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK," PharmacoEconomics, Springer, vol. 25(1), pages 39-54, January.
    18. Michelle Tew & Michael Willis & Christian Asseburg & Hayley Bennett & Alan Brennan & Talitha Feenstra & James Gahn & Alastair Gray & Laura Heathcote & William H. Herman & Deanna Isaman & Shihchen Kuo , 2022. "Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Chal," Medical Decision Making, , vol. 42(5), pages 599-611, July.
    19. Sandra Tunis, 2011. "Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin," Applied Health Economics and Health Policy, Springer, vol. 9(6), pages 351-365, November.
    20. Shuyan Gu & Yiming Mu & Suodi Zhai & Yuhang Zeng & Xuemei Zhen & Hengjin Dong, 2016. "Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-25, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Grossman, Michael, 2004. "The demand for health, 30 years later: a very personal retrospective and prospective reflection," Journal of Health Economics, Elsevier, vol. 23(4), pages 629-636, July.
    2. Schokkaert, Erik & Van de Voorde, Carine, 2004. "Risk selection and the specification of the conventional risk adjustment formula," Journal of Health Economics, Elsevier, vol. 23(6), pages 1237-1259, November.
    3. Perelman, Julian & Shmueli, Amir & Closon, Marie-Christine, 2008. "Deriving a risk-adjustment formula for hospital financing: Integrating the impact of socio-economic status on length of stay," Social Science & Medicine, Elsevier, vol. 66(1), pages 88-98, January.
    4. Amir Marashi & Shima Ghassem Pour & Vincy Li & Chris Rissel & Federico Girosi, 2019. "The association between physical activity and hospital payments for acute admissions in the Australian population aged 45 and over," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-16, June.
    5. Manning, Willard G. & Mullahy, John, 2001. "Estimating log models: to transform or not to transform?," Journal of Health Economics, Elsevier, vol. 20(4), pages 461-494, July.
    6. Cantoni, Eva & Ronchetti, Elvezio, 2006. "A robust approach for skewed and heavy-tailed outcomes in the analysis of health care expenditures," Journal of Health Economics, Elsevier, vol. 25(2), pages 198-213, March.
    7. Manos Matsaganis & Theodore Mitrakos & Panos Tsakloglou, 2009. "Modelling health expenditure at the household level in Greece," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(3), pages 329-336, July.
    8. Michael Keane & Olena Stavrunova, 2011. "A smooth mixture of Tobits model for healthcare expenditure," Health Economics, John Wiley & Sons, Ltd., vol. 20(9), pages 1126-1153, September.
    9. Jeonghoon Ahn, 2004. "Panel Data Sample Selection Model: an Application to Employee Choice of Health Plan Type and Medical Cost Estimation," Econometric Society 2004 Far Eastern Meetings 560, Econometric Society.
    10. Hall, Peter A. & Gingerich, Daniel W., 2004. "Varieties of Capitalism and Institutional Complementarities in the Macroeconomy," MPIfG Discussion Paper 04/5, Max Planck Institute for the Study of Societies.
    11. Jena, Anupam B. & Philipson, Tomas J., 2008. "Cost-effectiveness analysis and innovation," Journal of Health Economics, Elsevier, vol. 27(5), pages 1224-1236, September.
    12. Joan Costa-Fonta & Montserrat Font-Vilalta, "undated". "The limits on the Design of Long-Term Care Insurance Schemes in Spain stas," Studies on the Spanish Economy 201, FEDEA.
    13. Lisa M. Powell & Frank J. Chaloupka, 2005. "Parents, public policy, and youth smoking," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 24(1), pages 93-112.
    14. Vallury, Sechindra & Abbott, Joshua K. & Shin, Hoon C. & Anderies, John M., 2020. "Sustaining Coupled Irrigation Infrastructures: Multiple Instruments for Multiple Dilemmas," Ecological Economics, Elsevier, vol. 178(C).
    15. Clark, Andrew E. & Milcent, Carine, 2018. "Ownership and hospital behaviour: Employment and local unemployment," Social Science & Medicine, Elsevier, vol. 202(C), pages 151-161.
    16. Ruhm, Christopher J. & Black, William E., 2002. "Does drinking really decrease in bad times?," Journal of Health Economics, Elsevier, vol. 21(4), pages 659-678, July.
    17. Jan R. Magnus & Wendun Wang & Xinyu Zhang, 2016. "Weighted-Average Least Squares Prediction," Econometric Reviews, Taylor & Francis Journals, vol. 35(6), pages 1040-1074, June.
    18. Akbar Marvasti, 2007. "Foreign-Born Teaching Assistants and Student Achievement: An Ordered Probit Analysis," The American Economist, Sage Publications, vol. 51(2), pages 61-71, October.
    19. Martin Gaynor, "undated". "What Do We Know About Competition and Quality in Health Care Markets?," GSIA Working Papers 2006-E62, Carnegie Mellon University, Tepper School of Business.
    20. Nathan H. Miller, 2008. "Competition When Consumers Value Firm Scope," EAG Discussions Papers 200807, Department of Justice, Antitrust Division.

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:22:y:2002:i:4:p:340-349. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.